StockWatch
·
Biotechnology: Pharmaceutical Preparations
Corporate ActionJun 26, 2026, 04:13 PM

Soligenix Increases At-Market Offering by $2.5M

AI Summary

Soligenix, Inc. filed a prospectus supplement to increase the maximum aggregate offering amount of its common stock under an At Market Issuance Sales Agreement by an additional $2,500,000. The company had previously sold approximately $6,234,000 of common stock under the same agreement, which originally covered up to $6,406,000.

Key Highlights

  • Increased maximum aggregate offering amount by an additional $2,500,000.
  • Total additional common stock offering now stands at $2,500,000.
  • Previously sold approximately $6,234,000 of common stock under the Sales Agreement.
  • Prior prospectus supplements covered up to $6,406,000 of common stock.